The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
The FDA deserves kudos for drawing a line in the sand over their review of Covid-19 vaccines. They’ve made it clear — after deep skepticism …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.